Table I. Clinical and laboratory features of the subjects used as a source of IgG.
| VT+/PM− (n=10) |
VT−/PM+ (n=10) |
VT+/PM+ (n=7) |
aPL+/APS− (n=12) |
aPL-negative (n=10) |
|
|---|---|---|---|---|---|
| Age (mean yrs±SEM) | 51.8±4.8 | 57.1±3.3 | 45.3±3.4 | 50.4±4.4 | 33.6±2.9 |
| Sex | 1Male/9Female | 10Female | 7Female | 1Male/11Female | 1Male/9Female |
| PAPS | 5(50%) | 7(70%) | 6(86%) | 0 | 0 |
| SAPS | 5(50%) | 3(30%) | 1(14%) | 0 | 0 |
| Other ARD | 5SLE | 3SLE | 1SLE | 9SLE | 0 |
| Live Births | 8 | 17 | 7 | 8 | 4 |
| Total APS− related PM | 0 | 20 (10FT, 10ST, 1 pre- eclampsia) |
13 (4FT, 6ST, 1 pre- eclampsia) |
0 | 0 |
| Arterial – VT | 5 (3stroke, 5TIA) |
0 | 6 (5stroke) | 0 | 0 |
| Venous – VT | 5 (4DVT, 1PE) | 0 | 6 (4DVT, 3PE) |
0 | 0 |
| LA positive | 8 (80%) | 9 (90%) | 6, 1NT | 3 (25%) | 0 |
| aCL (mean GPLU±SEM) |
62.5±8.8 | 52.2±9.5 | 77.3±12.2 | 33.4±4.9 | 0 |
| Anti-β2GPI* (mean OD±SEM) |
148 (0.90±0.12) |
136 (0.83±0.09) |
90 (0.69±0.15) |
26 (0.18±0.06) |
0 |
| Aspirin | 3 | 8 | 2 | 4 | 0 |
| Warfarin | 10 | 2§ | 6 | 0 | 0 |
| Corticosteroids** | 3 | 1 | 1 | 6 | 0 |
| Immunosuppressives** | 2 | 2 | 1 | 7 | 0 |
Abbreviations: aCL, anticardiolipin; GPLU, IgG phospholipid units; ARD, Autoimmune rheumatic disease; DVT, Deep Vein Thrombosis; FT, First trimester; ST, Second trimester; PL, Pregnancy Loss; TIA, Transient Ischaemic Attack; PE, pulmonary embolus; SLE, Systemic Lupus Erythematosus; LA, Lupus Anticoagulant; NT, Not Tested.
Anti-β2GPI activity was calculated as mean % binding to a concentration of 100μg/ml HCAL.
In the VT+/PM− group one patient was taking 7mg prednisolone, a second was taking 100mg azathioprine and a third patient 10mg prednisolone and 100mg azathioprine. In the VT−/PM+ group one patient was taking 4mg prednisolone and 50mg azathioprine whilst another patient was taking 400mg hydroxychloroquine. Two of the VT−/PM+ were given warfarin on clinicians judgement for primary prevention and/or warfarin responsive headache with normal brain scan.